search archive

Browse

Previous Next

H.866~Susan Barrett~Follow-up information, re GMCB subpoena authority in statutes~3-31-2016

Object Type: Asset
In Folder: H.866

Other Documents

sdb:SO|5684db67-92fc-4c61-be19-f5ecfa0895f1

40

Amended 2015 Guide to Vermonts Prescribed Product Gift Ban and Disclosure Law – Final

IO_6827c2cd-5c70-497a-ab43-7f4550082825

H.866~Andrew MacLean~Keeping a lid on drug prices, by Jeffrey S. Flier, Dean, Harvard Medical School~4-18-2016

IO_e1787bc8-56f8-440e-9a50-57b97e14f053

H.866~Andrew MacLean~Testimony from PhRMA–Vermont Pharmaceutical Cost Transparency~4-15-2016

IO_a692b221-649c-420f-b30a-9006dc56a199

H.866~Anne Donahue~Rep. Donahue proposed amendment~4-21-2016

IO_e9c9d42d-3440-4f3d-bc71-305a8c6fc44b

H.866~Anne Donahue~Rep. Donahue proposed strike-all, with Findings language~4-20-2016

IO_244cef41-0665-44b0-ba2b-f270972dfe03

H.866~Bill Lippert~Reuters Report, 4-4-16- Makers took big price increases on widely used U.S. drugs~4-5-2016

IO_c5cc253b-70ed-45e2-9711-ef4d58e3a6de

H.866~Bob Bancroft~Rep. Bancroft proposed amendment~4-21-2016

IO_12ffa805-6fc5-495c-b5da-a32f730cc922

H.866~Chris Pearson~Chris Pearson proposed strike-all amendment~4-14-2016

IO_baf5359e-4c7c-4a44-b775-5fb2022417cb

H.866~Chris Pearson~Draft No. 2.1, 4-15-2016~4-15-2016

IO_f6ac216d-50c1-4d2b-b4de-336aa2690a81

H.866~Dagny Hoff~Medicare drug plans and comparisons~4-6-2016

IO_f4bf4ef6-5f17-4ae7-9e88-77a4439b7b78

H.866~James Love~Increasing the Transparency of Markets for Drugs, Vaccines, Diagnostics and Other Medical Technologies~3-30-2016

IO_a63c0fea-6cc7-4cc6-8857-310651b92c76

H.866~James Love~When governments mandate transparency of RandD costs, the details are important~3-30-2016

IO_f81f10e0-a165-4267-bf52-2403b2a15318

H.866~Jennifer Carbee~As voted out, 4-21-16- Strike-all version, Draft 2.2~4-21-2016

IO_dcc4b155-d551-4250-9e75-e06ad018ed25

H.866~Jim McCullough~Amendment re Complementary and Alternative Medicine~3-31-2016

IO_36df4560-5c41-447b-81f4-f46ba8c39f82

H.866~Jim McCullough~CAM and Integrative Health Reduce Pharmaceutical Utilization~3-31-2016

IO_7bd41b50-ed5a-40c6-a6b4-25338733e9a1

H.866~Jim McCullough~Testimony on Complementary and Alternative Medicine~3-31-2016

IO_13fc6a50-6d1a-4791-849b-cb99c482c903

H.866~John Murphy~PhRMA–Innovative Biopharmaceutical Companies Disclose Wide Range of Data on Their Products~3-30-2016

IO_eebd91a9-74f6-4885-81df-c1401cb5fb69

H.866~Kathryn Becker Van Haste~Summary of S.2023, Sen. Sanders’ Prescription Drug Affordability Act~3-23-2016

IO_ec46c3ef-deee-4fa9-a6ef-e6536c80cec3

H.866~Kathryn Becker Van Haste~Text of S.2023, Senator Sanders’ Prescription Drug Affordability Act~3-23-2016

IO_93e4d19e-4303-4901-8aab-1fdaadfdf03d

H.866~Leigh Purvis~AARP- Trends in Retail Prices of Prescription Drugs Widely Used by Older Americans~3-31-2016

IO_d2b13154-a9a3-47ca-9d60-149c04042d6c

H.866~Leigh Purvis~Biography, Leigh Purvis~3-31-2016

IO_bdd8528a-864e-4cdc-a01f-2511f0caf98c

H.866~Reshma Ramachandran~Letter from the National Physicians Alliance—Support the Pharmaceutical Cost Transparency Act of 2015~4-5-2016

IO_c628feda-2120-4aee-ba3b-f5c6a65a1f44

H.866~Reshma Ramachandran~Report–Medicines Use and Spending Shifts~4-5-2016

IO_688ac65e-dcb8-49af-bc97-d91ad6f321c2

H.866~Reshma Ramachandran~Report–Spending on Medicines Increased 13.1 Percent in 2014~4-5-2016

IO_cbfecd52-f059-47a1-a062-45b47e283cdf

H.866~Ritchard Engelhardt~Testimony of the Biotechnology Innovation Organization (BIO)~3-31-2016

IO_ec8aaf63-98db-41bd-8b4f-6684114749bd

Powered by Preservica

Vermont State Archives and Records Administration